MX337429B - Posologia y administracion de composiciones basadas en glucocortticoides. - Google Patents

Posologia y administracion de composiciones basadas en glucocortticoides.

Info

Publication number
MX337429B
MX337429B MX2012013254A MX2012013254A MX337429B MX 337429 B MX337429 B MX 337429B MX 2012013254 A MX2012013254 A MX 2012013254A MX 2012013254 A MX2012013254 A MX 2012013254A MX 337429 B MX337429 B MX 337429B
Authority
MX
Mexico
Prior art keywords
administration
glucocorticoid
based compositions
posology
enabling
Prior art date
Application number
MX2012013254A
Other languages
English (en)
Other versions
MX2012013254A (es
Inventor
Thomas Hedner
Stanko Skrtic
Hans Lennernäs
Gudmundur Johannsson
Ulrika Sigrida Helena Simonsson
Original Assignee
Duocort Pharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42953726&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX337429(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Duocort Pharma Ab filed Critical Duocort Pharma Ab
Publication of MX2012013254A publication Critical patent/MX2012013254A/es
Publication of MX337429B publication Critical patent/MX337429B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a un método mejorado de administración de composiciones basadas en glucocorticoides en terapias de reemplazo de glucocorticoides que hace posible un régimen basado objetivamente para la administración que hace posible una dosificación individual, correcta de glucocorticoides que da por resultado una terapia de reemplazo individual, optimizada y de esta manera un resultado mejorado a largo plazo para pacientes con insuficiencia adrenal temporal o crónica.
MX2012013254A 2010-05-20 2011-05-18 Posologia y administracion de composiciones basadas en glucocortticoides. MX337429B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201000442 2010-05-20
PCT/EP2011/002466 WO2011144327A1 (en) 2010-05-20 2011-05-18 Posology and administration of glucocorticoid based compositions

Publications (2)

Publication Number Publication Date
MX2012013254A MX2012013254A (es) 2013-01-24
MX337429B true MX337429B (es) 2016-03-04

Family

ID=42953726

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012013254A MX337429B (es) 2010-05-20 2011-05-18 Posologia y administracion de composiciones basadas en glucocortticoides.

Country Status (15)

Country Link
US (2) US20130209565A1 (es)
EP (1) EP2571505B1 (es)
JP (1) JP2013526552A (es)
KR (1) KR20130099815A (es)
CN (1) CN102933218A (es)
AU (1) AU2011254959A1 (es)
BR (1) BR112012029466A2 (es)
CA (1) CA2799820A1 (es)
CL (1) CL2012003152A1 (es)
CO (1) CO6660433A2 (es)
IL (1) IL223000A0 (es)
MX (1) MX337429B (es)
PE (1) PE20131024A1 (es)
SG (2) SG10201506611XA (es)
WO (1) WO2011144327A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0401031D0 (sv) 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
GB201119985D0 (en) 2011-11-19 2012-01-04 Diurnal Ltd Treatment of adrenal insufficiency
US10262112B2 (en) * 2013-02-04 2019-04-16 Precera Bioscience, Inc. Prescription decision support system and method using comprehensive multiplex drug monitoring
GB201308933D0 (en) 2013-05-17 2013-07-03 Diurnal Ltd Paediatric composition
ES2967617T3 (es) * 2013-12-06 2024-05-03 Bioverativ Therapeutics Inc Herramientas de farmacocinética poblacional y sus usos
US20160367755A1 (en) * 2015-06-01 2016-12-22 Massachusetts Institute Of Technology System and method for neuroendocrine control
CN107115308B (zh) * 2016-02-23 2021-02-23 天津金耀集团有限公司 一种氢化可的松双相缓释片剂组合物
CN108553436A (zh) * 2018-06-08 2018-09-21 华益药业科技(安徽)有限公司 一种20mg氢化可的松片处方和工艺规程
US12451248B2 (en) * 2018-08-17 2025-10-21 The Regents Of The University Of California Diagnosing hypoadrenocorticism from hematologic and serum chemistry parameters using machine learning algorithm

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0119848D0 (en) * 2001-08-15 2001-10-10 Univ Sheffield Delayed and sustained drug release
SE0401031D0 (sv) 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
US20120183610A1 (en) * 2009-04-07 2012-07-19 Lennernaes Hans glucocorticoid therapy

Also Published As

Publication number Publication date
KR20130099815A (ko) 2013-09-06
AU2011254959A1 (en) 2013-01-10
CO6660433A2 (es) 2013-04-30
PE20131024A1 (es) 2013-10-10
CL2012003152A1 (es) 2013-07-12
MX2012013254A (es) 2013-01-24
EP2571505B1 (en) 2016-07-06
SG185457A1 (en) 2012-12-28
JP2013526552A (ja) 2013-06-24
CA2799820A1 (en) 2011-11-24
WO2011144327A1 (en) 2011-11-24
SG10201506611XA (en) 2015-09-29
IL223000A0 (en) 2013-02-03
BR112012029466A2 (pt) 2017-03-01
US20150209375A1 (en) 2015-07-30
US20130209565A1 (en) 2013-08-15
CN102933218A (zh) 2013-02-13
EP2571505A1 (en) 2013-03-27

Similar Documents

Publication Publication Date Title
MX337429B (es) Posologia y administracion de composiciones basadas en glucocortticoides.
MX2013002488A (es) Métodos y composiciones para suministrar un antagonista del receptor interleucina-1.
MX371344B (es) Antagonistas de il-4r para usarse en el tratamiento o prevención de asma persistente y asma severa.
PH12015500545A1 (en) Methods for modulating corticosterone levels in psychologically stressed individuals
MX346224B (es) Composiciones y metodos para el tratamiento de inflamacion cronica y enfermedades inflamatorias.
WO2014153069A3 (en) Compositions and methods for reprogramming hematopoietic stem cell lineages
WO2011031524A3 (en) Methods and compositions for delivering interleukin-1 receptor antagonist
BR112015005048A2 (pt) métodos para tratar dermatite atópica por administração de antagonista il-4r
EP4523696A3 (en) Enhanced adoptive cell therapy
EA201791738A1 (ru) Пролипосомальные композиции тестостерона
GB2502032A (en) Vitamin D composition
WO2014134084A3 (en) Phf20 and jmjd3 compositions and methods of use in cancer immunotherapy
MX2021006111A (es) Composicion farmaceutica que comprende un anticuerpo anti-gm-csf para usarse en el tratamiento de artritis reumatoide.
EP2744482A4 (en) STEROID HORMONE DELIVERY SYSTEMS AND METHODS OF PREPARATION THEREOF
NZ701949A (en) Combination treatments and compositions for wound healing
MX2012007898A (es) Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor.
PH12013502663A1 (en) Dosage administration of anti-erbb3 antibodies in combination with paclitaxel for treatment of gynecological cancers
IL227355A0 (en) Treatment preparations that combine a glucocorticoid receptor antagonist and a steroid
EP3063172A4 (en) Methods of measuring potential for therapeutic potency and defining dosages for autologous cell therapies
NZ628454A (en) Combination therapy of anti-mif antibodies and glucocorticoids
IL282635A (en) Oral administration of therapeutic mammalian cells
MX2015004703A (es) Composiciones cancerigenas inyectables.
MX2014008693A (es) Administracion transdermica de hormonas.
MX2016011706A (es) Formulaciones de progesterona.
UA66405U (ru) Способ профилактики плацентарной дисфункции у беременных с пиелонефритом

Legal Events

Date Code Title Description
FG Grant or registration